Mobia Medical, Inc.
No SEC Form 4 filings for $MOBI in the last 30 days.
See all $MOBI insider activity →Mobia Medical, Inc. (MOBI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 mobi-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Mobia Medical Reports Second Quarter 2026 Financial Results Austin, Texas, August 11, 2026 — Mobia Medical, Inc. (Nasdaq: MOBI), a medical device company redefining stroke recovery for survivors living with life-altering moto
Mobia Medical, Inc. (MOBI) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001489993 0001489993 2026-07-30 2026-07-30 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30,
Mobia Medical, Inc. (Nasdaq: MOBI) said it appointed Reza Zadno, Ph.D., as an independent director effective July 14, 2026. Zadno will also sit on the Compensation Committee. The company cited his experience leading public medical technology firms through IPOs and commercial expansion, including roles at PROCEPT BioRobotics and Avedro.
Over the past 7 days, alphai's AI scored 1 news story mentioning MOBI (Mobia Medical, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent MOBI coverage spans insider activity, corporate actions and earnings.
The 8-K provides fresh quarterly results plus a specific FY revenue range, which can reset near-term expectations for a post-IPO medtech growth story.
Board expansion and a new independent director appointment is unlikely to drive near-term fundamentals, but it can modestly affect governance sentiment.
Board/compensation committee change may modestly affect governance and executive pay oversight, but it is not a direct operational or financial catalyst.
Board and Compensation Committee composition changes are typically low-to-moderate signal for governance and oversight, with limited direct operational impact.
The Neurology publication strengthens clinical durability evidence for Vivistim Paired VNS Therapy, which can support adoption and future commercial/coverage momentum.
alphai scores every news story that mentions MOBI with an AI model for sentiment and relevance, and aggregates insider trades from Mobia Medical, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Mobia Medical, Inc. (MOBI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 mobi-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Mobia Medical Reports Second Quarter 2026 Financial Results Austin, Texas, August 11, 2026 — Mobia Medical, Inc. (Nasdaq: MOBI), a medical device company redefining stroke recovery for survivors living with life-altering moto
4 min readMobia Medical, Inc. (MOBI) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001489993 0001489993 2026-07-30 2026-07-30 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30,
2 min readMobia Medical, Inc. (Nasdaq: MOBI) said it appointed Reza Zadno, Ph.D., as an independent director effective July 14, 2026. Zadno will also sit on the Compensation Committee. The company cited his experience leading public medical technology firms through IPOs and commercial expansion, including roles at PROCEPT BioRobotics and Avedro.
2 min readMobia Medical, Inc. (MOBI) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K 0001489993 false 0001489993 2026-07-14 2026-07-14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14,
2 min readMobia Medical (Nasdaq: MOBI) said Neurology published two-year follow-up results from its VNS-REHAB trial of Vivistim Paired VNS Therapy in chronic ischemic stroke. Among 49 participants, 76% met response on FMA-UE and/or WMFT, with average gains of +7.5 FMA-UE and +0.63 WMFT. Mobia reported improvements in daily living and quality of life sustained for at least two years.
4 min readMobia Medical (Nasdaq: MOBI) said CMS proposed keeping CPT 64568 for its Vivistim procedure in New Technology APC 1580 for CY2027, with an outpatient hospital payment rate of about $45,000, unchanged from CY2026. CMS plans to issue the final OPPS rule in November, effective Jan. 1, 2027.
3 min readGreen Park & Golf Ventures - Houston, LLC purchased 60,537 indirectly-held shares of Mobia Medical, Inc. (MOBI) at $15.00 ($0.91M total) on 2026-05-11.
2 min readGreen Park & Golf Ventures II, LLC purchased 33,333 indirectly-held shares of Mobia Medical, Inc. (MOBI) at $15.00 ($0.50M total) on 2026-05-11.
2 min readGreen Park & Golf Ventures II, LLC sold 6,731 indirectly-held shares of Mobia Medical, Inc. (MOBI) on 2026-05-11.
1 min readGreen Park & Golf Ventures II, LLC purchased 81,000 indirectly-held shares of Mobia Medical, Inc. (MOBI) at $15.00 ($1.22M total) on 2026-05-11.
2 min read
